Johnson & Johnson annual free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson Free Cash Flow (FCF) History (JNJ)
Johnson & Johnson reported $19.70B in free cash flow for fiscal 2025, a decrease of 0.73% from the previous fiscal year, with a free cash flow margin of 20.91%.
View full Johnson & Johnson company overviewJohnson & Johnson free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-28 | $19.70B | −$144.0M | −0.73% | +20.91% |
| 2024 | 2024-12-29 | $19.84B | $1.59B | +8.74% | +22.34% |
| 2023 | 2023-12-31 | $18.25B | $1.06B | +6.19% | +21.43% |
| 2022 | 2023-01-01 | $17.18B | −$2.57B | −13.02% | +21.48% |
| 2021 | 2022-01-02 | $19.76B | −$431.0M | −2.13% | +25.09% |
| 2020 | 2021-01-04 | $20.19B | $271.0M | +1.36% | +24.45% |
| 2019 | 2019-12-29 | $19.92B | $1.39B | +7.48% | +24.27% |
| 2018 | 2018-12-30 | $18.53B | $754.0M | +4.24% | +22.71% |
| 2017 | 2017-12-31 | $17.78B | $2.24B | +14.39% | +23.25% |
| 2016 | 2017-01-01 | $15.54B | −$565.0M | −3.51% | +21.62% |
| 2015 | 2016-01-03 | $16.11B | $1.11B | +7.40% | +22.98% |
| 2014 | 2014-12-28 | $15.00B | $1.18B | +8.52% | +20.17% |
| 2013 | 2013-12-29 | $13.82B | $1.36B | +10.89% | +19.38% |
| 2012 | 2012-12-30 | $12.46B | $1.06B | +9.27% | +18.54% |
| 2011 | 2012-01-01 | $11.40B | −$2.60B | −18.54% | +17.54% |
| 2010 | 2011-01-02 | $14.00B | −$205.0M | −1.44% | +22.73% |
| 2009 | 2010-01-03 | $14.21B | $2.30B | +19.32% | +22.95% |
| 2008 | 2008-12-28 | $11.91B | −$174.0M | −1.44% | +18.68% |
| 2007 | 2007-12-30 | $12.08B | — | — | +19.77% |
Johnson & Johnson quarterly free cash flow
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $7.29B | $4.46B | +157.32% | +28.82% |
| Q1 2026 | 2026-03-29 | $1.47B | −$1.91B | −56.64% | +6.09% |
| Q4 2025 | 2025-12-28 | $5.47B | $101.0M | +1.88% | +22.28% |
| Q3 2025 | 2025-09-28 | $8.01B | $1.05B | +15.05% | +33.39% |
| Q2 2025 | 2025-06-29 | $2.83B | −$1.82B | −39.12% | +11.94% |
| Q1 2025 | 2025-03-30 | $3.38B | $529.0M | +18.56% | +15.43% |
| Q4 2024 | 2024-12-29 | $5.37B | −$903.0M | −14.39% | +23.85% |
| Q3 2024 | 2024-09-29 | $6.96B | $442.0M | +6.78% | +30.99% |
| Q2 2024 | 2024-06-30 | $4.66B | $1.60B | +52.29% | +20.75% |
| Q1 2024 | 2024-03-31 | $2.85B | $456.0M | +19.05% | +13.33% |
| Q4 2023 | 2023-12-31 | $6.27B | $2.51B | +66.73% | +29.32% |
| Q3 2023 | 2023-10-01 | $6.52B | $1.19B | +22.32% | +30.55% |
| Q2 2023 | 2023-07-02 | $3.06B | −$1.66B | −35.18% | +14.21% |
| Q1 2023 | 2023-04-02 | $2.39B | −$978.0M | −29.00% | +11.46% |
| Q4 2022 | 2023-01-01 | $3.76B | −$554.0M | −12.83% | +18.87% |
| Q3 2022 | 2022-10-02 | $5.33B | −$2.21B | −29.31% | +26.67% |
| Q2 2022 | 2022-07-03 | $4.72B | $217.0M | +4.82% | +23.34% |
| Q1 2022 | 2022-04-03 | $3.37B | −$25.0M | −0.74% | +17.00% |
| Q4 2021 | 2022-01-02 | $4.32B | −$2.70B | −38.50% | +44.19% |
| Q3 2021 | 2021-10-03 | $7.54B | −$103.0M | −1.35% | +32.32% |
| Q2 2021 | 2021-07-04 | $4.50B | $1.71B | +61.33% | +19.31% |
| Q1 2021 | 2021-04-04 | $3.40B | $664.0M | +24.30% | +15.22% |
| Q4 2020 | 2021-01-04 | $7.02B | $1.88B | +36.63% | +31.23% |
| Q3 2020 | 2020-09-27 | $7.65B | $864.0M | +12.74% | +36.27% |
| Q2 2020 | 2020-06-28 | $2.79B | −$2.32B | −45.41% | +15.22% |
| Q1 2020 | 2020-03-29 | $2.73B | −$154.0M | −5.33% | +13.21% |
| Q4 2019 | 2019-12-29 | $5.14B | $212.0M | +4.30% | +24.77% |
| Q3 2019 | 2019-09-29 | $6.78B | $1.33B | +24.37% | +32.72% |
| Q2 2019 | 2019-06-30 | $5.11B | −$93.0M | −1.79% | +24.86% |
| Q1 2019 | 2019-03-31 | $2.89B | −$61.0M | −2.07% | +14.42% |
| Q4 2018 | 2018-12-30 | $4.93B | $61.0M | +1.25% | +24.15% |
| Q3 2018 | 2018-09-30 | $5.45B | −$23.0M | −0.42% | +26.80% |
| Q2 2018 | 2018-07-01 | $5.20B | $121.0M | +2.38% | +24.98% |
| Q1 2018 | 2018-04-01 | $2.95B | $595.0M | +25.29% | +14.73% |
| Q4 2017 | 2017-12-31 | $4.87B | −$695.0M | −12.50% | +24.09% |
| Q3 2017 | 2017-10-01 | $5.48B | $852.0M | +18.43% | +27.87% |
| Q2 2017 | 2017-07-02 | $5.08B | $1.28B | +33.52% | +26.98% |
| Q1 2017 | 2017-04-02 | $2.35B | $803.0M | +51.81% | +13.24% |
| Q4 2016 | 2017-01-01 | $5.56B | $1.84B | +49.50% | +30.71% |
| Q3 2016 | 2016-10-02 | $4.62B | −$727.0M | −13.59% | +25.95% |
| Q2 2016 | 2016-07-03 | $3.81B | −$900.0M | −19.12% | +20.60% |
| Q1 2016 | 2016-04-03 | $1.55B | −$779.0M | −33.45% | +8.87% |
| Q4 2015 | 2016-01-03 | $3.72B | $611.0M | +19.66% | +20.88% |
| Q3 2015 | 2015-09-27 | $5.35B | $1.45B | +37.10% | +31.29% |
| Q2 2015 | 2015-06-28 | $4.71B | $15.0M | +0.32% | +26.46% |
| Q1 2015 | 2015-03-29 | $2.33B | −$964.0M | −29.27% | +13.41% |
| Q4 2014 | 2014-12-28 | $3.11B | $398.0M | +14.69% | +17.03% |
| Q3 2014 | 2014-09-28 | $3.90B | −$1.24B | −24.04% | +21.13% |
| Q2 2014 | 2014-06-29 | $4.69B | $412.0M | +9.63% | +24.07% |
| Q1 2014 | 2014-03-30 | $3.29B | $1.60B | +94.74% | +18.18% |
| Q4 2013 | 2013-12-29 | $2.71B | $486.0M | +21.85% | +14.76% |
| Q3 2013 | 2013-09-29 | $5.14B | $840.0M | +19.54% | +29.23% |
| Q2 2013 | 2013-06-30 | $4.28B | $633.0M | +17.36% | +23.94% |
| Q1 2013 | 2013-03-31 | $1.69B | −$602.0M | −26.25% | +9.66% |
| Q4 2012 | 2012-12-30 | $2.22B | −$99.0M | −4.26% | +12.67% |
| Q3 2012 | 2012-09-30 | $4.30B | $387.0M | +9.90% | +25.21% |
| Q2 2012 | 2012-07-01 | $3.65B | $356.0M | +10.82% | +22.14% |
| Q1 2012 | 2012-04-01 | $2.29B | $413.0M | +21.97% | +14.21% |
| Q4 2011 | 2012-01-01 | $2.32B | −$542.0M | −18.92% | +14.29% |
| Q3 2011 | 2011-10-02 | $3.91B | −$595.0M | −13.20% | +24.44% |
| Q2 2011 | 2011-07-03 | $3.29B | −$46.0M | −1.38% | +19.83% |
| Q1 2011 | 2011-04-03 | $1.88B | −$1.41B | −42.91% | +11.62% |
| Q4 2010 | 2011-01-02 | $2.87B | −$1.58B | −35.52% | +18.31% |
| Q3 2010 | 2010-10-03 | $4.51B | −$69.0M | −1.51% | +30.08% |
| Q2 2010 | 2010-07-04 | $3.34B | $541.0M | +19.35% | +21.77% |
| Q1 2010 | 2010-04-04 | $3.29B | $901.0M | +37.67% | +21.07% |
| Q4 2009 | 2010-01-03 | $4.44B | — | — | +26.84% |
| Q3 2009 | 2009-09-27 | $4.58B | $454.0M | +11.02% | +30.34% |
| Q2 2009 | 2009-06-28 | $2.80B | — | — | +18.35% |
| Q1 2009 | 2009-03-29 | $2.39B | — | — | +15.92% |
| Q3 2008 | 2008-09-28 | $4.12B | — | — | +25.88% |
Johnson & Johnson free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $20.19B to $19.70B, a compound annual decline of 0.49%. Johnson & Johnson's latest reported quarter, Q2 2026, generated $7.29B in free cash flow, an increase of 157.32% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Johnson & Johnson source filings ↗Community posts
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
